Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Conditions
Adult Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Previously Untreated Childhood Rhabdomyosarcoma | Stage IV Adult Soft Tissue Sarcoma
What is the purpose of this trial?
This clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.
Participation Guidelines
- Age:
- 1 Month - 49 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- National Cancer Institute (NCI)
- Dates:
- July 2012
- Last Updated:
- April 1, 2013
- Study HIC#:
- 1207010532
Clinicaltrials.gov ID: NCT01055314




